The FDA approval of daraxonrasib is a milestone in oncology, transforming a growth driver into a potentially treatable ...

Study of breast cancer survivors shows that depression and stress, rather than cardiac function decline, are the primary ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Weighing a harder early adjustment period against that benefit is an ongoing, individualized conversation, she says, with no one-size-fits-all answer in an era of precision medicine. Her takeaway for ...

Monotherapy remains worth considering for patients who live far from a cancer center or who are older or more frail, for whom combination treatment may be too demanding, says Amanda Edmond, PA-C, of ...

Many patients require a dose interruption or reduction, and MARIPOSA showed efficacy remained consistent despite modifications, so Edmond treats dosing as adaptable and works to find the right dose ...

Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy. Amanda Edmond, PA-C, of Banner MD ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia vera. FDA approves BESREMi (ropeginterferon ...